Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 1985Hematological Oncology

Heterogeneity of response and survival in diffuse histiocytic lymphoma after bacop therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone)

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAlexandra M. LevineCity of HopeMGMark A. GoldsteinUniversity of Southern CaliforniaPMPaul R. MeyerNorthwestern University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Levine et al. (1985) studied this question.

synapsesocial.com/papers/6a1eeae35b601e8f2e050210https://doi.org/10.1002/hon.2900030203
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Utility of Lymphocyte Surface Markers Combined with the Lukes-Collins Histologic Classification in Adult Lymphoma1979 · 129 citations
  2. 2Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)1982 · 128 citations
  3. 3T-cell lymphomas of large cell type. A variety of malignant lymphomas: “Histiocytic” and mixed lymphocytic-“histiocytic”1980 · 74 citations
  4. 4Cyclophosphamide, Vincristine, Methotrexate with Leucovorin Rescue, and Cytarabine (COMLA) Combination Sequential Chemotherapy for Advanced Diffuse Histiocytic Lymphoma1980 · 159 citations
  5. 5Nonparametric Estimation from Incomplete Observations1958 · 39,532 citations